BREAKING NEWS BRIEF
A vaccine against malaria has shown record efficacy in a Phase II trial, raising hopes that one of the world’s most deadly diseases could be brought under control. The vaccine, developed by Oxford and known as R21, showed up to 77% efficacy in a trial of 450 children in Burkina Faso over 12 months.
The shot was the first to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a malaria vaccine with at least 75% efficacy. Oxford’s study inoculated 450 children between the ages of 5 to 17 months. They were split into three groups, and researchers reported the higher dose group was 77% less likely to get the disease. It was noted that there were “no serious adverse events related to the vaccine,”
Malaria is a parasitic disease transmitted through the bite of female Anopheles mosquitoes. It is both preventable and treatable, yet an estimated 435,000 people die of it each year, with the majority being children younger than five.
ry precautions. The single case along the torch route would not affect the subsequent legs of the relay.
Additional News Headlines
- California goes from worst to first in virus infections
- This is how heavy marijuana use in pregnancy will affect the baby
- Elon Musk comments on the SpaceX Crew-2 launch
- George Clooney says this has been a disaster for his marriage
- This celebrity announces she will run for governor as a Republican
P.S.Know someone who’d love the Brief Updates? Be sure to send them to this link so they can get signed up: BriefUpdates.com